Fig 1: SARS-CoV-2 uses neuropilin-1 as immune evasion strategy by inhibiting type I IFNa production from pDCs AThe effect of CD304 signaling on IFNa production was tested by incubating pDCs and peripheral blood isolated pDCs (blood pDC) with anti-CD304 antibody (aCD304) or isotype control antibody (isot ctrl) (10 µg/ml) for 15 min prior to stimulation with TLR7 agonist (2.5 µg/ml R837). Cell culture supernatants were harvested after 24 h to quantify type I IFNa by ELISA. Data is normalized to isotype control IFNa levels for each cell population.BInference of CRISPR Edits (ICE) analysis of CD304KO pDCs.C–EAAVS1KO and CD304KO pDCs were either mock treated (mock) or exposed to SARS-CoV-2 (1 MOI), cell culture supernatants were collected at indicated times and analyzed for type I IFNa (C) IL-6 (D) and CXCL10 (E) protein concentrations. Data information: Bars represent mean values, equal symbols represent equal donors (n = 4–5). Statistical significance was determined using the ratio paired student T test for agonist or virus-treated cells and compared to the time point-matched mock-treated condition, or by unpaired T test when comparing matched conditions between different KOs. *P < 0.05, **P < 0.01, ns = not significant.